



ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

February 6, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 6, 2018-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

- **Leerink Partners 7th Annual Global Healthcare Conference**
February 15 at 3:30pm ET
- **RBC Capital Markets 2018 Global Healthcare Conference**
February 21 at 2:35pm ET
- **Cowen and Company 38th Annual Health Care Conference**
March 13 at 8:40am ET

A webcast of each presentation will be accessible through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay will be available at the same location for approximately two weeks.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR α -positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla[®], and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla[®] is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Transition Report on Form 10-K for the fiscal year ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180206005916/en/>

Source: ImmunoGen, Inc.

For Investors
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com

or

For Media
ImmunoGen, Inc.
Courtney O'Konek, 781-895-0600
courtney.okonek@immunogen.com

or

FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com